|
Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease
RECRUITINGPhase 2Sponsored by NewAmsterdam Pharma
Actively Recruiting
PhasePhase 2
SponsorNewAmsterdam Pharma
Started2026-09
Est. completion2028-09
Eligibility
Age55 Years – 85 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →
NCT07794670
Summary
A study evaluating Obicetrapib in adults potentially at risk for Preclinical Alzheimer's Disease
Eligibility
Age: 55 Years – 85 YearsHealthy volunteers accepted
Inclusion Criteria: * participants with preclinical AD Exclusion Criteria: * APOE genotype not meeting protocol-defined eligibility criteria
Conditions2
Alzheimer's DiseasePreclinical Alzheimer's Disease
Interventions2
Locations1 site
K2 Medical Research
Find trials near these locations
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 2
SponsorNewAmsterdam Pharma
Started2026-09
Est. completion2028-09
Eligibility
Age55 Years – 85 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →
NCT07794670